TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003–15 6
Financial performance, 2003–15 7
Lundbeck: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 10
Chapter 3 Quarterly update 17
Latest quarterly sales 17
Latest comment 17
Latest prescription pharma product news 18
Latest corporate news 19
Chapter 4 Company introduction 20
Key findings 20
Background 21
Key corporate developments 21
M&A history 21
Current corporate structure 21
Chapter 5 Company sales 22
Key findings 22
Prescription pharmaceutical sales and growth rate analysis, 2003–15 23
Product analysis 24
Therapy area analysis 29
Geographic analysis 31
Launch/core/expiry analysis 33
Molecule type analysis 37
Externalization analysis 39
Chapter 6 Company financials 41
Key findings 41
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09 42
Operating costs and profit analysis 43
Chapter 7 Key products and competitors 48
Overview 48
Cipralex (including Lexapro royalties) 49
Ebixa 52
Chapter 8 Appendix 54
References 54
Abbreviations 54
Exchange rates 55
About Datamonitor 56
Datamonitor consulting 56
Disclaimer 58
TABLE OF TABLES
Table 1: Lundbeck – PharmaVitae forecasts at a glance 8
Table 2: Lundbeck quarterly sales ($m), Q309-Q310 17
Table 3: Lundbeck product portfolio overview ($m), 2003–09 25
Table 4: Lundbeck product portfolio overview ($m), 2009–15 27
Table 5: Lundbeck prescription pharmaceutical sales by therapy area ($m), 2009–15 30
Table 6: Lundbeck prescription pharmaceutical sales by geographic region ($m), 2009–15 32
Table 7: Lundbeck launch portfolio overview ($m), 2009-15 34
Table 8: Lundbeck core portfolio overview ($m), 2009-15 35
Table 9: Lundbeck expiry portfolio overview ($m), 2009-15 35
Table 10: Lundbeck prescription pharmaceutical sales by molecule type ($m), 2009-15 38
Table 11: Lundbeck prescription pharmaceutical sales by source ($m), 2009-15 40
Table 12: Total Lundbeck sales by business unit ($m), 2003-09 42
Table 13: Lundbeck operating revenue/cost analysis ($m), 2003–09 44
Table 14: Lundbeck operating cost ratio analysis (% of total revenues), 2003-09 45
Table 15: Lundbeck operating cost ratio analysis (% of total revenues), 2009-15 46
Table 16: Lundbeck operating revenue/cost analysis ($m), 2009-15 47
Table 17: Key products overview 48
Table 18: Cipralex: overview 49
Table 19: Cipralex: sales forecast ($m), 2008–14 50
Table 20: Ebixa: overview 52
Table 21: Ebixa: sales forecast ($m), 2009-15 53
Table 22: Exchange rates, 2010 55
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Lundbeck prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 6
Figure 3: Lundbeck’s financial performance ($m), 2003–15 7
Figure 4: Share of CNS market in 5EU and ‘rest of world’ by company (%), 2009–15 9
Figure 5: Lundbeck SWOT analysis 10
Figure 6: Lundbeck prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 23
Figure 7: Key product sales ($m), 2003-15 24
Figure 8: Lundbeck key sales growth drivers and resistors ($m), 2003–09 26
Figure 9: Lundbeck key sales growth drivers and resistors ($m), 2009–15 28
Figure 10: Lundbeck prescription pharmaceutical sales by therapy area ($m), 2003–15 29
Figure 11: Lundbeck prescription pharmaceutical sales by geographic region ($m), 2003–15 31
Figure 12: Lundbeck launch/core/expiry configuration ($m), 2009-15 36
Figure 13: Lundbeck prescription pharmaceutical sales by molecule type ($m), 2003–15 37
Figure 14: Lundbeck prescription pharmaceutical sales by source ($m), 2003-15 39
Figure 15: Lundbeck operating revenue/cost analysis ($m), 2003–15 43
[Inhaltsverzeichnis ausblenden]
